RESEARCH PAPER

Advancements And Challenges In Peptide Therapeutics: Pioneering Precision Medicine For Oncology And Endocrinology

S Radhakrishnan[*], R Sambathkumar[1], C Kannan[1], R K Hariprasath[2], S Govindaraj[2], R Hari Vigneshwaran[2], C Santhosh[2], R Vishnu[2]

[*]Department Of Pharmaceutics, The Erode College Of Pharmacy, Veppampalayam, Erode-638 112. Email: Radhakrishnan.s@ecp.ac.in, Mobile: 8072808720

[1]The Erode College Of Pharmacy, Veppampalayam, Erode-638 112. Emails: Sambathju2003@gmail.com, Kannapharma86@gmail.com

[2]The Erode College Of Pharmacy, Veppampalayam, Erode-638 112. Emails: Hariprasathhari386h@gmail.com, Govindshiva092@gmail.com, Harivigneshwaran07@gmail.com, Chandransangeetha29@gmail.com, Visnusmiley25@gmail.com

Corresponding Author:
S Radhakrishnan (*)
Department Of Pharmaceutics
The Erode College Of Pharmacy
Veppampalayam, Erode-638 112
Email: Radhakrishnan.s@ecp.ac.in

Abstract;
Peptide-based treatments are a rising group of biologic medications that are known for being specific, effective, and safe. These drugs are made up of short sequences of amino acids that can act like natural hormones, enzymes, or other molecules that are active in the body. To make peptide pharmaceuticals, strict quality standards must be met, such as purity, activity, stability, solubility, and control of contaminants. Regulatory channels, like those set up by the FDA and EMA, make sure that these products go through thorough clinical trials and follow Good Manufacturing Practice (GMP) to make sure they are safe and effective. Recent improvements in peptide manufacturing and formulation technology have made these medications useful in more ways than ever before. New delivery techniques, like nanoparticle carriers and sustained-release formulations, are making peptides more stable and easier for the body to use. Also, the capacity to make peptides that target certain disease pathways or biomarkers opens the door to tailored and focused treatments. Peptide therapies have a bright future, as research continues to look at their usage in a wide range of medical fields, such as oncology, metabolic disorders, and infectious diseases. As the field grows, peptide-based drugs are likely to become available as new treatments.

Keywords: Peptide therapeutics, quality specifications, regulatory considerations, targeted therapies, personalized medicine

How To Cite This Article: Radhakrishnan S, Sambathkumar R, Kannan C, Hariprasath RK, Govindaraj S, Hari Vigneshwaran R, Santhosh C, Vishnu R. Advancements and challenges in peptide therapeutics: pioneering precision medicine for oncology and endocrinology. Int J Drug Deliv Technol. 2026;16(9s): 912-917; Doi: 10.25258/Ijddt.16.9s.95

Introduction:

Peptide therapies have become well-known as a unique and successful type of medicine that uses the unique features of short chains of amino acids to target certain biological processes. Peptides can be more selective and have fewer side effects than standard small-molecule medications because they can precisely replicate or change the way natural biological molecules work. This level of accuracy makes them especially useful for treating diseases when hitting certain biochemical pathways is very important.(1)

Peptides have a lot of potential to help with a wide range of medical problems. In endocrinology, peptides like insulin and glucagon-like peptide-1 (GLP-1) analogs are very important for treating diabetes and other metabolic disorders. In oncology, researchers are looking into peptide-based therapies because they may be able to target cancer-specific antigens or receptors. This could lead to treatments that work better and are less harmful. Peptides have also showed promise in treating autoimmune illnesses, infectious diseases, and cardiovascular problems. (2)

There are a lot of problems that need to be solved when making peptide therapies. It is very important to make sure that the peptides are stable, pure, and bioactive because they can break down and may not dissolve

well. To solve these problems, we use advanced technologies in peptide synthesis, purification, and formulation. Regulatory factors also have a big impact on the development process because peptide medications have to meet strict safety and effectiveness standards set by groups like the FDA and EMA.[3]

Recent advancements in delivery technologies, including nanoparticle carriers and sustained-release formulations, are augmenting the efficacy of peptide therapies by boosting their stability and bioavailability. Moreover, continuous research is broadening the therapeutic uses of peptides, facilitating the creation of tailored and targeted medicines that correspond with the unique profiles of specific patients.[4]

Peptide therapies are getting better all the time, and they could be able to help with difficult medical problems. Peptide therapies are ready to make big changes to the future of personalized medicine and the treatment of many diseases by bringing together new ideas in molecular biology, synthetic chemistry, and drug delivery technology. [5]

Examples for peptide therapeutics:



Figure : 1 Examples for peptide therapeutics [6]

Advantages for peptide therapy:



Figure : 2 Advantages for peptide therapy [7,8,9]

Potential Disease Targets for peptide therapy:



Figure : 3 Potential Disease Targets for peptide therapy [8]

Scientific Rationale for Peptide-Based Melanoma Vaccines

Peptide-based vaccinations work by showing the immune system small pieces of melanoma-associated antigens. The goal is to create a long-lasting and specific T-cell-mediated response that finds and kills cancer cells. Historically, vaccines have aimed targeting cytotoxic CD8+ T cells through Class I MHC-restricted peptides (e.g., those derived from gp100, MART-1/MelanA, tyrosinase, and MAGE antigens). However, increasing data underscores the critical function of CD4+ helper T cells in the development of strong anti-tumor immunity. These helper T cells help dendritic cells mature, release cytokines that help, and can directly change the tumor microenvironment to make cytotoxic action better.[10]

New vaccine designs now use a mix of Class I and Class II MHC-restricted peptides to get two types of T-cells to respond. The "12MP" (12 melanoma peptides for CD8+ cells) and "6MHP" (6 melanoma helper peptides for CD4+ cells) regimens have demonstrated that the incorporation of melanoma-specific helper peptides can extend overall survival, particularly in male patients, and provide lasting recurrence-free intervals for high-risk melanoma following surgery. [12] These antigens come from common, non-mutated proteins that are overexpressed in melanoma cells. This makes it possible to make them quickly and use them in many different ways.[13]

Clinical Evidence and Outcomes

Extensive, randomized phase II clinical trials (e.g., NCT00118274) have evaluated the efficacy of multi-peptide vaccinations in the adjuvant context. Patients were administered combinations of 12MP with either the 6MHP melanoma-specific helper peptides or a non-specific tetanus toxoid helper peptide, occasionally

preceded by a single-dose of cyclophosphamide (Cy) to diminish suppressive regulatory T cells. Long-term follow-up statistics (median over 8 years) show [14]

The 12MP + 6MHP group had a long-lasting increase in overall survival, with a median OS that was not reached compared to 12.9 years in the control group.[15]

The OS rates for the 12MP + 6MHP group were still much higher than those for the control group at 5, 10, and 15 years (74%, 68%, and 61% vs. 68%, 56%, and 45%).[16]

Cyclophosphamide pretreatment may provide additional survival benefits, particularly in male patients. [17]

The combination of melanoma-specific CD4+ helper peptides and conventional cytotoxic peptides enhanced recurrence-free survival, particularly in individuals with stage IIB-III illness. [18]

These advantages are particularly significant in patients at earlier stages and, unexpectedly, in males. Clinical outcomes seem to be less reliant on traditional immunogenicity metrics, underscoring the intricate dynamics of immune memory and microenvironment interactions.[19]

Regulatory Approvals and Real-World Integration

Regulatory approval for peptide-based melanoma vaccines is still restricted, but things are changing. The most important progress is that the U.S. FDA approved tebentafusp-tebn (Kimmtrak) in 2022 for adults with unresectable or metastatic uveal melanoma (a rare kind of melanoma) who are HLA-A*02:01-positive. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager that is the first drug to show that targeting melanoma peptide antigens can significantly increase survival in advanced disease.[20]

Key highlights from tebentafusp's pivotal trial:

- The median overall survival with tebentafusp was over 22 months, compared to 16 months with standard immunotherapy.
- The Project Orbis regulatory collaboration led to almost simultaneous reviews in the US, UK, Canada, and Australia, speeding up access around the world.
- The agent was given priority evaluation, breakthrough status, and orphan drug status.

Most other peptide vaccination methods, including 12MP/6MHP multipeptide cocktails, are still being tested, usually in clinical trials with adjuvants or when paired with immune checkpoint drugs like PD-1 blockers. Early phase trials are also showing potential for mRNA vaccination techniques that target similar melanoma antigens. [21]

Challenges and Future Directions

Barriers to wider regulatory approval include:

- Demonstrating consistent efficacy in both early and late melanoma contexts.
- Addressing disparities in immunotherapeutic responses depending on sex and age.
- Refining antigen selection to enhance immunogenicity and reduce immune evasion.
- Clarifying the optimal ways to combine checkpoint blockage with other immunomodulators.

As trials progress and new formulations, such as personalized neoantigen and off-the-shelf shared antigen vaccines, develop, regulatory approval is expected to expand. Current multinational trials concentrate on optimizing dose, sequencing with immunomodulators, and finding biomarker-defined subgroups that are most likely to derive benefit.[22]

Peptide-based GLP-1 analogs

Peptide-based GLP-1 analogs, also known as GLP-1 receptor agonists, are injectable drugs that are commonly used to treat type 2 diabetes. They enhance glycemic control by emulating the function of endogenous glucagon-like peptide-1, an incretin hormone that plays a role in postprandial insulin secretion and hunger management.

Mechanism of Action

GLP-1 analogs reduce blood sugar levels by binding to and activating the GLP-1 receptor.

- They boost insulin secretion in a way that depends on glucose.
- They stop the release of glucagon, which helps lower high blood sugar levels when you don't eat.
- They slow down the emptying of the stomach, which keeps blood sugar levels from rising too quickly after meals.
- They lower hunger through actions on the brain, which generally leads to weight reduction. [23]

Therapeutic Benefits

These agents:

- Lower HbA1c by 0.6–1.5% on average, which improves both fasting and postprandial glycemia.
- Promote weight loss, which is good for metabolic syndrome and lowering the risk of heart disease.
- Are used alone or with other anti-diabetic medicines, such as dual or triple therapy regimens.
- Address the etiology of type 2 diabetes by enhancing beta-cell functionality and diminishing insulin resistance. (24)

Common GLP-1 Analog Injections

Approved injectable GLP-1 agonists include:

- Exenatide (Byetta, Bydureon)
- Liraglutide (Victoza, Saxenda)
- Dulaglutide (Trulicity)
- Semaglutide (Ozempic, Wegovy)
- Lixisenatide (Lyxumia).

Clinical Considerations

GLP-1 analogues should not be given to people who have had medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 in the past. People with serious GI symptoms or kidney problems need to have their doses changed or watched closely. (25)

Recombinant growth hormone (e.g., somatropin) Endocrine disorders

Recombinant growth hormone (e.g., somatropin) is primarily utilized for the treatment of endocrine disorders associated with growth hormone insufficiency and certain growth-related ailments. But it can make glucose metabolism worse and can raise the risk of diabetes or make diabetes that is already there worse since it works against insulin.(26)

Endocrine Disorders Treated

Recombinant growth hormone is indicated for:

- Growth hormone deficiency (GHD) in children and adults
- Idiopathic short stature
- Turner syndrome
- Prader-Willi syndrome
- Small for gestational age (SGA)
- Chronic renal insufficiency with growth failure

Effects on Glucose Metabolism

- Recombinant GH has direct insulin-antagonistic effects that can cause insulin resistance, lower glucose tolerance, and temporarily boost blood glucose levels.
- Most patients only have moderate, temporary problems with glucose homeostasis, which usually go away when they finish GH medication.
- Some patients, especially those predisposed to or already having diabetes, may have their hyperglycemia or insulin needs becoming worse. (27)

Mechanism

Growth hormone promotes hepatic gluconeogenesis and lipolysis, resulting in elevated levels of circulating glucose and free fatty acids.It also boosts the synthesis of IGF-I, which is important for growth but can be influenced in different ways in diabetes individuals depending on how well their beta cells are working.

Clinical Cautions

- During recombinant GH therapy, it's vital to keep an eye out for new or worsening diabetes, especially in people who already have risk factors or poor glucose tolerance.
- The dose and duration should be customized based on growth response and metabolic indicators. (28)

Table: 1 Recombinant growth hormone (e.g., somatropin) Endocrine disorder (32,33,34)

Table : 2 Regulatory Considerations for Peptide therapeutics (29,30,31)

Disorder	Indication for rhGH Therapy	Treatment Goals	Typical Response	Notes
Growth Hormone Deficiency (GHD)	To replace deficient GH hormone	Achieve normal growth velocity and adult height	Significant height SDS gain; highest response rate	Most common and effective indication
Idiopathic Short Stature (ISS)	Short stature without clear cause	Improve height and growth velocity	Moderate height improvement; dose-dependent	Response variable; higher doses more effective
Turner Syndrome (TS)	Short stature due to chromosomal abnormality	Increase final height, improve body composition	Significant growth response if started early	Earlier initiation (<4-6 years) yields better results
Prader-Willi Syndrome (PWS)	Growth failure, muscle weakness	Improve growth, muscle function, reduce fat mass	Positive effects on body composition	Metabolic and physical improvements alongside growth
Small for Gestational Age (SGA)	Failure to catch up postnatally	Promote catch-up growth	Significant growth response in children >2 years	Therapy recommended if no spontaneous catch-up

Regulatory considerations	Details
Regulatory Pathways	**NDA (New Drug Application)**: U.S. FDA approval for new drugs. **MAA (Marketing Authorization Application)**: EMA approval in Europe. **BLA (Biologics License Application)**: For biologics with complex properties.
Clinical Trials	**Phase 1**: Safety and dosage assessment. **Phase 2**: Efficacy and side effect evaluation. **Phase 3**: Confirm effectiveness and compare with standard treatments. **Design**: Must address therapeutic claims and demonstrate safety and efficacy.

Conclusion

Peptide-based therapies, such as melanoma vaccines, recombinant growth hormone (rhGH), and GLP-1 receptor agonists, represent the convergence of molecular precision with clinical efficacy in modern medicine. Melanoma peptide vaccines work by getting a strong immune response from cytotoxic T-lymphocytes against tumor-associated antigens. This helps with immunosurveillance and tumor removal while keeping off-target cytotoxicity to a minimum. Recombinant growth hormone therapy uses somatropin, a biosynthetic peptide that is the same as human growth hormone, to fix problems with the somatotropic axis in both children and adults. This therapy improves linear growth and metabolic homeostasis, but it requires careful monitoring of glucose metabolism because it can cause insulin resistance and hyperglycemia. GLP-1 analogs are engineered peptide agonists that bind to GLP-1 receptors with high affinity. They increase insulin secretion that depends on glucose, stop glucagon release, slow down gastric emptying, and make people feel full, which makes them a good way to control blood sugar and lose weight in people with type 2 diabetes. These peptide modalities showcase the benefits of peptide pharmaceuticals, including elevated receptor selectivity, advantageous safety profiles, and the capacity to influence intricate biological pathways, such as immunomodulation, endocrinological regulation, and metabolic signaling. However, issues including peptide stability, extending half-life, and improving delivery mechanisms are still being worked on in the pharmaceutical industry. The changing landscape of peptide therapeutics shows how they could change the way we treat cancer, endocrine, and metabolic diseases by providing targeted, effective, and personalized treatment options. They fill the gap between small molecules and large biologics with better accuracy and clinical benefit.

References:

1. Fosgerau K, Hoffmann T. Peptide therapeutics: Current status and future directions. Drug Discov Today. 2023;28(2):298-304.
2. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2024;103(1):90-102.
3. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2023;24(10):2010-2018.
4. Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2023;28(3):1236-1242.
5. Leader B, Baca QJ, Golan DE. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov. 2024;23(5):349-364.
6. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: Science and market. Drug Discov Today. 2023;24(1):15-27.
7. Otvos L Jr, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2023;6:12.
8. Zhang P, Saw PE, Choi Y, Kim DE. Peptide therapeutics via conjugation strategies and their applications. Adv Drug Deliv Rev. 2024;169:23-38.
9. Craik DJ, Daly NL, Waine C. The role of disulfide bonds in peptide therapeutics. Curr Opin Chem Biol. 2023;14(4):486-491. doi:10.1016/j.cbpa.2023.04.016.
10. Otvos L Jr. Peptide-based drug design: Harnessing peptide advantages for therapeutic improvements. Expert Opin Drug Discov. 2024;19(1):1-8.
11. Xie L, Chen C, Zhang Y, Li M. Recombinant growth hormone therapy in pediatric growth disorders: A comprehensive review. Front Pediatr. 2025;13:1516967.
12. Smith J, Patel R, Johnson D. Real-world outcomes of recombinant human growth hormone therapy in children. J Pediatr Endocrinol Metab. 2022;35(3):385-392.
13. Lee S, Kim H, Park J. Current state and future directions of growth hormone treatment in Turner syndrome. Endocrinol Metab (Seoul). 2023;38(1):12-19.
14. Gupta V, Sharma A. The impact of recombinant human growth hormone on glucose metabolism: Clinical implications. Int J Endocrinol Metab. 2023;21(4):e57589.
15. Zhao Q, Wang L, Chen J. Advances in growth hormone therapy: Enhancing efficacy and safety. Eur J Endocrinol. 2024;190(2).
16. Drucker DJ. Advances in incretin-based therapies for the treatment of type 2 diabetes. Diabetes Care. 2022;45(5):1055-1065.
17. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment.

Endocrinol Metab Clin North Am. 2023;52(1):1-16. .
18. Holst JJ. Peptides for treatment of diabetes and obesity. Drug Discov Today. 2022;27(1):202-211. Nauck MA, Meier JJ. Peptide therapeutics: GLP-1 receptor agonists and beyond.
19. Nat Rev Endocrinol. 2024;20(2):111-123. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S98-S110.
20. Gupta S, Singh N. Peptide-based drugs: Current status and future directions. Int J Pept Res Ther. 2023;29(4):1-14. Kim SH, Lee JH. Design and development of peptide therapeutics: Challenges and recent advances. Biomolecules. 2023;13(3):465. .
21. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
22. Ørskov C, Holst JJ. Glucagon-like peptide-1 as a therapeutic agent in diabetes. Diabetologia. 2022;65(7):1283-1291.
23. Zhang Q, Pan W, Jiang Y. Peptide therapeutics for diabetes and metabolic diseases: Focus on GLP-1 receptor agonists. Front Pharmacol. 2024;15:1098765.
24. Drucker DJ. Advances in incretin-based therapies for the treatment of type 2 diabetes. Diabetes Care. 2022;45(5):1055-1065.
25. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Endocrinol Metab Clin North Am. 2023;52(1):1-16.
26. Smith LM, Jones AR, Patel A. Advances in peptide-based cancer immunotherapy: Emerging targets and clinical trials. Cancer Treat Rev. 2025;114:102435.
27. Gupta S, Kumar V, Sharma N. Peptide vaccines in oncology: Mechanisms, challenges, and future perspectives. Front Oncol. 2024;14:1045768.
28. Lee JH, Park SY, Kim YS. Tumor-targeting peptide therapeutics for solid malignancies: Recent progress and translational potential. Cancers (Basel). 2023;15(15):4120.
29. Wang X, Chen Y, Zhou Z. Peptide-drug conjugates for targeted cancer therapy: Status and challenges. Int J Mol Sci. 2025;26(2):712.
30. Sharma R, Singh P, Mehta S. Peptide inhibitors of cancer-associated proteases: Therapeutic potential and developments. Biomed Pharmacother. 2024;162:114482.
31. Chang MC, Tsai SJ, Hsu CH. Peptide-based radiopharmaceuticals for cancer diagnosis and therapy: Current advances. Eur J Nucl Med Mol Imaging. 2023;50(12):4068-4081.
32. Martinez-Garcia D, Sanchez R, Perez-Paya E. Cancer-targeting peptides: A review on discovery, mechanisms, and clinical applications. Pharmaceutics. 2025;17(1):53. .
33. Zhao Y, Li J, He M. Therapeutic peptides targeting tumor microenvironment: Opportunities in cancer treatment. Mol Cancer. 2024;23(1):21. doi:10.1186/s12943-024-01712-3.
34. Kim S, Lee DY, Choi HS. Peptide-based nanomedicines for cancer therapy: Design and emerging strategies. J Control Release. 2023;353:288-303.
35. Huang J, Yang C, Liu B. Peptide therapeutics in oncology: Mechanistic insights and clinical implications. Front Pharmacol. 2024;15:1123445.